Bente Langdahl1, Lorenz C Hofbauer2, Serge Ferrari3, Zhenxun Wang4, Astrid Fahrleitner-Pammer5, Evelien Gielen6, Péter Lakatos7, Edward Czerwinski8, Esteban Jódar Gimeno9, Jen Timoshanko10, Mary Oates4, Cesar Libanati11. 1. Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark. bente.langdahl@aarhus.rm.dk. 2. Technische Universität Dresden, Dresden, Germany. 3. Geneva University Hospital, Geneva, Switzerland. 4. Amgen Inc., Thousand Oaks, CA, USA. 5. Medical University of Graz, Graz, Austria. 6. University Hospital Leuven, Leuven, Belgium. 7. Semmelweis University, Budapest, Hungary. 8. Krakow Medical Centre, Krakow, Poland. 9. Hospital Universitario Quiron Salud Madrid, Universidad Europea, Madrid, Spain. 10. UCB Pharma, Slough, UK. 11. UCB Pharma, Brussels, Belgium.
Abstract
In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated with large gains in bone mineral density. INTRODUCTION: In the multinational FRAME phase 3 trial of romosozumab in postmenopausal women with osteoporosis, marked differences between clinical and non-vertebral fracture outcomes were observed among patients from Central and Southern America versus rest of world. This post hoc analysis assessed romosozumab efficacy and safety in European patients enrolled in the FRAME trial and extension study. METHODS: In FRAME (NCT01575834), patients were randomised 1:1 to romosozumab 210 mg or placebo monthly (QM) for 12 months, followed by open-label denosumab 60 mg Q6M to month 36, including a 12-month extension study. We report incidence of major fracture outcomes, bone mineral density (BMD) change from baseline and safety for European patients enrolled in FRAME. RESULTS: In FRAME, 3013/7180 (41.96%) patients were European; 1494 received romosozumab and 1519 received placebo. Through 12 months, romosozumab reduced fracture risk versus placebo for non-vertebral fracture (1.4% versus 3.0%; p = 0.004), clinical fracture (1.4% versus 3.6%; p < 0.001), new vertebral fracture (0.4% versus 2.1%; p < 0.001) and major osteoporotic fracture (0.9% versus 2.8%; p < 0.001), with results sustained through 36 months following transition to denosumab. Hip fractures were numerically reduced with romosozumab at month 12 (0.2% versus 0.6%; p = 0.092). Romosozumab increased BMD versus placebo at month 12; all patients in the romosozumab and placebo groups experienced further increases by month 36 after transition to denosumab. Adverse events were balanced between groups. CONCLUSIONS: Among European patients in FRAME, romosozumab resulted in early and sustained risk reduction for all major fracture categories, associated with large BMD gains that continued after transition to denosumab.
In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated with large gains in bone mineral density. INTRODUCTION: In the multinational FRAME phase 3 trial of romosozumab in postmenopausal women with osteoporosis, marked differences between clinical and non-vertebral fracture outcomes were observed among patients from Central and Southern America versus rest of world. This post hoc analysis assessed romosozumab efficacy and safety in European patients enrolled in the FRAME trial and extension study. METHODS: In FRAME (NCT01575834), patients were randomised 1:1 to romosozumab 210 mg or placebo monthly (QM) for 12 months, followed by open-label denosumab 60 mg Q6M to month 36, including a 12-month extension study. We report incidence of major fracture outcomes, bone mineral density (BMD) change from baseline and safety for European patients enrolled in FRAME. RESULTS: In FRAME, 3013/7180 (41.96%) patients were European; 1494 received romosozumab and 1519 received placebo. Through 12 months, romosozumab reduced fracture risk versus placebo for non-vertebral fracture (1.4% versus 3.0%; p = 0.004), clinical fracture (1.4% versus 3.6%; p < 0.001), new vertebral fracture (0.4% versus 2.1%; p < 0.001) and major osteoporotic fracture (0.9% versus 2.8%; p < 0.001), with results sustained through 36 months following transition to denosumab. Hip fractures were numerically reduced with romosozumab at month 12 (0.2% versus 0.6%; p = 0.092). Romosozumab increased BMD versus placebo at month 12; all patients in the romosozumab and placebo groups experienced further increases by month 36 after transition to denosumab. Adverse events were balanced between groups. CONCLUSIONS: Among European patients in FRAME, romosozumab resulted in early and sustained risk reduction for all major fracture categories, associated with large BMD gains that continued after transition to denosumab.
Authors: Tineke A C M Laurs-van Geel; Jacqueline R Center; Piet P Geusens; Geert-Jan Dinant; John A Eisman Journal: Maturitas Date: 2010-10-06 Impact factor: 4.342
Authors: E Michael Lewiecki; Rajani V Dinavahi; Marise Lazaretti-Castro; Peter R Ebeling; Jonathan D Adachi; Akimitsu Miyauchi; Evelien Gielen; Cassandra E Milmont; Cesar Libanati; Andreas Grauer Journal: J Bone Miner Res Date: 2018-12-03 Impact factor: 6.741
Authors: Mary L Bouxsein; Richard Eastell; Li-Yung Lui; Lucy A Wu; Anne E de Papp; Andreas Grauer; Fernando Marin; Jane A Cauley; Douglas C Bauer; Dennis M Black Journal: J Bone Miner Res Date: 2019-01-23 Impact factor: 6.741
Authors: Felicia Cosman; Daria B Crittenden; Serge Ferrari; Aliya Khan; Nancy E Lane; Kurt Lippuner; Toshio Matsumoto; Cassandra E Milmont; Cesar Libanati; Andreas Grauer Journal: J Bone Miner Res Date: 2018-05-17 Impact factor: 6.741
Authors: Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer Journal: N Engl J Med Date: 2016-09-18 Impact factor: 91.245
Authors: Elizabeth Barrett-Connor; Ethel S Siris; Lois E Wehren; Paul D Miller; Thomas A Abbott; Marc L Berger; Arthur C Santora; Louis M Sherwood Journal: J Bone Miner Res Date: 2004-10-18 Impact factor: 6.741
Authors: Felicia Cosman; Daria B Crittenden; Serge Ferrari; E Michael Lewiecki; Juan Jaller-Raad; Cristiano Zerbini; Cassandra E Milmont; Paul D Meisner; Cesar Libanati; Andreas Grauer Journal: J Bone Miner Res Date: 2018-05-11 Impact factor: 6.741